Trial Profile
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms ReLive
- Sponsors BioAlliance Pharma; Onxeo SA; Valerio Therapeutics
- 29 Aug 2019 Status changed from active, no longer recruiting to completed.
- 06 Jul 2019 This trial has been completed in Austria, according to European Clinical Trials Database.
- 08 May 2019 This trial has been completed in Spain, according to European Clinical Trials Database.